Skip to main content
Alphamab Oncology logo

Alphamab Oncology — Investor Relations & Filings

Ticker · 9966 ISIN · KYG0330A1013 LEI · 254900VOW925DTFGNA02 HKEX Manufacturing
Open in API
Filings indexed 361 across all filing types
Latest filing 2025-06-30 Board/Management Inform…
Country KY Cayman Islands
Listing HKEX 9966

About Alphamab Oncology

http://www.alphamabonc.com

Alphamab Oncology is an innovative biopharmaceutical company specializing in the research, development, and commercialization of differentiated anti-tumor biotherapeutics. The company is dedicated to addressing unmet clinical needs in oncology by developing effective, safe, and globally competitive cancer therapies. A core unique selling point is its proprietary technology platform for Antibody-Drug Conjugates (ADCs). This platform utilizes site-specific conjugation via Fc glycan, employing a one-enzyme, two-step process to produce ADCs with a highly uniform Drug-to-Antibody Ratio (DAR). This method results in superior serum stability and enhanced bystander killing effect, aiming to widen the therapeutic window and minimize toxic side effects. Key pipeline assets include KN035 and the biparatopic HER2-targeting ADC, JSKN003, which has received Breakthrough Therapy Designation from the FDA.

Recent filings

Filing Released Lang Actions
LIST OF DIRECTORS AND THEIR ROLES AND FUNCTIONS
Board/Management Information Classification · 1% confidence The document provides a list of the company’s board members, their titles, and committee memberships. There is no financial data, voting results, legal proceedings, or transcript content. It clearly constitutes a Board/Management Information announcement.
2025-06-30 English
(1) CHANGE OF INDEPENDENT NON-EXECUTIVE DIRECTORS&#x3b; AND (2) CHANGE IN COMPOSITION OF THE BOARD COMMITTEES
Board/Management Information Classification · 1% confidence The document is an official Hong Kong Exchange announcement detailing the resignation and appointment of independent non-executive directors and changes to board committee composition. It specifically addresses changes in the company’s board of directors, fitting the category for Board/Management Information (MANG).
2025-06-30 English
POLL RESULTS OF ANNUAL GENERAL MEETING HELD ON JUNE 12, 2025
Declaration of Voting Results & Voting Rights Announcements Classification · 1% confidence The document is titled “POLL RESULTS OF ANNUAL GENERAL MEETING HELD ON JUNE 12, 2025” and provides the formal vote counts on each resolution proposed at the AGM. It is not a full report (e.g., Annual Report or Interim Report), nor a notice of an upcoming meeting; rather it discloses the actual voting outcomes. This matches the definition of a "Declaration of Voting Results & Voting Rights Announcement".
2025-06-12 English
INSIDE INFORMATION ANNOUNCEMENT - COMPLETION OF PLACING OF EXISTING SHARES BY CONTROLLING SHAREHOLDER
Major Shareholding Notification Classification · 1% confidence The document is an inside information announcement under HKEx rules disclosing the completion of the placing of existing shares by a controlling shareholder, with a post-transaction shareholding table. It does not involve company share issuance/buy-back, nor is it an earnings, management or ESG report. It specifically notifies a change in significant share ownership levels. Therefore it best matches the Major Shareholding Notification category (MRQ).
2025-06-06 English
Monthly Return of Equity Issuer on Movements in Securities for the month ended 31 May 2025
Regulatory Filings Classification · 1% confidence The document is a periodic regulatory return (Form FF301) filed with the Hong Kong Stock Exchange detailing monthly movements in authorised, issued, and treasury shares under Chapter 19B of the Listing Rules. It is neither an annual/interim report nor an earnings release, nor a specific category like a major shareholding threshold notice or proxy statement. It is a routine regulatory filing of share capital movements, fitting the fallback category for miscellaneous regulatory announcements. Therefore, it should be classified as a Regulatory Filing (RNS).
2025-06-04 English
VOLUNTARY ANNOUNCEMENT - RESEARCH UPDATES OF JSKN003 FOR PRESENTATION AT 2025 ASCO ANNUAL MEETING
Regulatory Filings Classification · 1% confidence The document is a voluntary announcement published on the Hong Kong Stock Exchange regarding clinical research updates of the company’s drug candidate JSKN003 presented at the 2025 ASCO Annual Meeting. It does not contain financial results, management changes, or any of the specific regulatory forms (earnings release, annual report, interim report, share issuance, dividend notice, etc.). It is a general corporate news announcement disclosing operational progress, which falls under the fallback category ‘Regulatory Filings (RNS)’ for miscellaneous disclosures not covered by more specific codes.
2025-06-03 English

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.